UY37631A - INHIBITOR OF THE REGULATORY KINASE OF THE APOPTOSIS SIGNAL - Google Patents
INHIBITOR OF THE REGULATORY KINASE OF THE APOPTOSIS SIGNALInfo
- Publication number
- UY37631A UY37631A UY0001037631A UY37631A UY37631A UY 37631 A UY37631 A UY 37631A UY 0001037631 A UY0001037631 A UY 0001037631A UY 37631 A UY37631 A UY 37631A UY 37631 A UY37631 A UY 37631A
- Authority
- UY
- Uruguay
- Prior art keywords
- inhibitor
- apoptosis signal
- regulatory kinase
- compound
- formula
- Prior art date
Links
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 230000006907 apoptotic process Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
- 230000001105 regulatory effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 abstract 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 abstract 1
- 208000002353 alcoholic hepatitis Diseases 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 208000038003 heart failure with preserved ejection fraction Diseases 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se proporciona un compuesto de Fórmula (I) o una sal farmacéuticamente aceptable del mismo para uso en el tratamiento de esteatohepatitis no alcohólica, hepatitis alcohólica, hipertensión arterial pulmonar, insuficiencia cardíaca con fracción de eyección conservada y enfermedad renal diabética. También se proporcionan formas amorfas y cristalinas del compuesto de Fórmula (I) y sales, co-cristales, solvatos e hidratos del mismo.A compound of Formula (I) or a pharmaceutically acceptable salt thereof is provided for use in the treatment of non-alcoholic steatohepatitis, alcoholic hepatitis, pulmonary arterial hypertension, heart failure with preserved ejection fraction and diabetic kidney disease. Amorphous and crystalline forms of the compound of Formula (I) and salts, co-crystals, solvates and hydrates thereof are also provided.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762471300P | 2017-03-14 | 2017-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY37631A true UY37631A (en) | 2018-09-28 |
Family
ID=61750538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001037631A UY37631A (en) | 2017-03-14 | 2018-03-14 | INHIBITOR OF THE REGULATORY KINASE OF THE APOPTOSIS SIGNAL |
Country Status (6)
| Country | Link |
|---|---|
| AR (1) | AR111178A1 (en) |
| BR (1) | BR102018004862A2 (en) |
| JO (1) | JOP20180017A1 (en) |
| TW (1) | TW201840551A (en) |
| UY (1) | UY37631A (en) |
| WO (1) | WO2018169742A1 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI598347B (en) | 2009-07-13 | 2017-09-11 | 基利科學股份有限公司 | Inhibitor of kinases that regulate apoptosis signaling |
| AU2018266911C1 (en) * | 2017-05-12 | 2022-10-20 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| US10597382B2 (en) | 2017-08-28 | 2020-03-24 | Enanta Pharmaceuticals, Inc. | Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| WO2019213239A1 (en) | 2018-05-02 | 2019-11-07 | Enanta Pharmaceuticals Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| ES3004523T3 (en) | 2018-05-02 | 2025-03-12 | Enanta Pharm Inc | Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| CN110818683B (en) * | 2018-08-10 | 2023-04-14 | 中国科学院上海药物研究所 | 2-pyridine substituted urea structure small molecular compound and its synthesis and application |
| WO2020041417A1 (en) | 2018-08-22 | 2020-02-27 | Enanta Pharmaceuticals, Inc. | Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| WO2020106707A1 (en) | 2018-11-19 | 2020-05-28 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| US11466033B2 (en) | 2019-03-25 | 2022-10-11 | Enanta Pharmaceuticals, Inc. | Substituted pyridines as apoptosis signal-regulating kinase 1 inhibitors |
| AU2021282582A1 (en) * | 2020-06-04 | 2023-02-02 | Curasen Therapeutics, Inc. | Forms and compositions of a beta adrenergic agonist |
| WO2023125904A1 (en) * | 2021-12-30 | 2023-07-06 | 苏州晶云药物科技股份有限公司 | Crystal form of azacyclobutyl nicotinic acid compound and preparation method therefor |
| CN119055775A (en) * | 2022-07-30 | 2024-12-03 | 中国医学科学院阜外医院 | Use of Jun inhibitors in the preparation of drugs for treating heart failure with preserved ejection fraction |
| CN117054652B (en) * | 2023-08-04 | 2024-05-17 | 南京医科大学 | A biomarker for assisting detection of myocardial hypertrophy and its application |
| CN118252938B (en) * | 2024-01-24 | 2025-02-11 | 中国医学科学院阜外医院 | Use of an agent for inhibiting or knocking out Jun gene expression for treating heart failure with preserved ejection fraction |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI598347B (en) | 2009-07-13 | 2017-09-11 | 基利科學股份有限公司 | Inhibitor of kinases that regulate apoptosis signaling |
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| UY34573A (en) | 2012-01-27 | 2013-06-28 | Gilead Sciences Inc | QUINASE INHIBITOR REGULATING THE APOPTOSIS SIGNAL |
| US20150342943A1 (en) | 2014-06-03 | 2015-12-03 | Gilead Sciences, Inc. | Methods of treating liver disease |
| TW201618781A (en) | 2014-08-13 | 2016-06-01 | 吉李德科學股份有限公司 | Methods of treating pulmonary hypertension |
| MA41252A (en) * | 2014-12-23 | 2017-10-31 | Gilead Sciences Inc | SOLID FORMS OF AN ASK 1 INHIBITOR |
-
2017
- 2017-03-14 JO JOP/2018/0017A patent/JOP20180017A1/en unknown
-
2018
- 2018-03-07 WO PCT/US2018/021334 patent/WO2018169742A1/en not_active Ceased
- 2018-03-12 BR BR102018004862A patent/BR102018004862A2/en not_active Application Discontinuation
- 2018-03-13 TW TW107108465A patent/TW201840551A/en unknown
- 2018-03-14 UY UY0001037631A patent/UY37631A/en not_active Application Discontinuation
- 2018-03-14 AR ARP180100585A patent/AR111178A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR111178A1 (en) | 2019-06-12 |
| TW201840551A (en) | 2018-11-16 |
| JOP20180017A1 (en) | 2019-01-30 |
| BR102018004862A2 (en) | 2019-01-02 |
| WO2018169742A1 (en) | 2018-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY37631A (en) | INHIBITOR OF THE REGULATORY KINASE OF THE APOPTOSIS SIGNAL | |
| AR106237A2 (en) | HETEROCYCLIC INHIBITORS OF ASPARTIL PROTEASA, ITS PHARMACEUTICALLY ACCEPTABLE SALTS | |
| CL2016000405A1 (en) | Use of methyl bardoxolon or analogues thereof for the treatment and / or prevention of endothelial dysfunction. | |
| ECSP20013248A (en) | DERIVATIVES OF 3- (1-OXOISOINDOLIN-2-IL) PIPERIDINE-2,6-DIONA AND USES OF THE SAME | |
| AR108768A2 (en) | PIRIDINE AND PIRAZOL COMPOUNDS AND THEIR USES FOR HEMOGLOBIN MODULATION | |
| CL2021002244A1 (en) | Jak inhibitor compound and use thereof | |
| AR117920A1 (en) | HUMAN IMMUNODEFICIENCY VIRUS REPLICATION INHIBITORS | |
| AR105238A1 (en) | BENZOXACEPIN OXAZOLIDINONE COMPOUNDS AND METHODS OF USE | |
| BR112015031864A2 (en) | pyrimidinedione compounds against cardiac conditions | |
| MX376856B (en) | EXTENDED-RELEASE DOSAGE FORMS FOR A JAK 1 (JANUS KINASE 1) INHIBITOR. | |
| AR124688A2 (en) | A PYRIMIDINE SULFONAMIDE OR A TAUTOMER THEREOF, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | |
| AR078411A1 (en) | IMIDAZOLIL VINYL COMPOUND AND PHARMACEUTICAL COMPOSITION THAT INCLUDES IT | |
| UY36314A (en) | NEW INTEGRINE ANTEGRON COMPOUNDS avß6. | |
| MA38078B1 (en) | Pyridine derivative | |
| EA201891780A1 (en) | DERIVATIVES OF SULPHONAMIDE AND CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS | |
| CL2021003342A1 (en) | Disubstituted pyrazole compounds as ketohexokinase inhibitors. | |
| MX2019013626A (en) | Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof. | |
| AR097866A1 (en) | 4-AZAINDOL DERIVATIVES | |
| CO6300953A2 (en) | MINERALCORTICOID RECEIVER ANTAGONISTS AND METHODS OF USE | |
| CR20210085A (en) | 2,6 diamino pyridine compounds | |
| CR20140462A (en) | SALTS OF 5 - [(1R) -2 - ({2- [4- (2,2-DIFLUORO-2-PHENYLETOXI) PHENYL] ETIL} AMINO) -1-HYDROXYETY] -8-HYDROQUINOLIN-2 (1H) - ONA | |
| HK1257555A1 (en) | Inhibitors of the tec kinase enzyme family | |
| MX2017000635A (en) | Inhibitors of the renal outer medullary potassium channel. | |
| MX2019005803A (en) | DERIVATIVE OF PYRID [3,4-D] PYRIMIDINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALT. | |
| DOP2018000134A (en) | 1,3,4-TIADIAZOL COMPOUNDS AND THEIR USE IN CANCER TREATMENT |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 104 | Application deemed to be withdrawn (no substantive examination fee paid) |
Effective date: 20201204 |